|   From the Trenches

SPR994: A Long Shot, With Lots Of Twists And Turns To Phase III

At Spero we are privileged to be enrolling our pivotal study for SPR994, our oral antibiotic with the bacteria-killing power of an IV to treat patients with serious urinary tract infections.  A frightening sign of our deteriorating antibiotic arsenal is the three million patients in the US alone whose infections do not respond to oral antibiotics used in past decades; if these patients are hospitalized they can cost an average of $4,000 more to treat than if an effective oral agent were available.  In this era of a value conscious health care system, there are few interventions that are more cost-effective than getting patients out of the hospital or keeping them out. SPR994 could provide the tool to make this happen.

This blog was written by Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. 

Read more.